EPA Reauthorizes Bt Corn

The U.S. Environmental Protection Agency announced on Oct. 16 that it had reauthorized commercial planting of genetically modified corn varieties transformed with genes from the bacterium Bacillus thuringiensis. Bt corn, as it's known, makes toxic Cry proteins lethal to caterpillars of the European corn borer and other damaging insects.1 The proteins are harmless to humans. As a result of EPA's action, seed companies can now market the products for another seven years, depending on compliance wi

Written byBarry Palevitz
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

EPA reached its decision after a year-long review of the crops. According to spokesperson David Deegan, the agency relied in part on advice from scientists asked to examine the matter. The scientific advisory panel, or SAP, reviewed risks and benefits of Bt corn, first planted in 1996. Says Stephen L. Johnson, assistant administrator of EPA's Office of Prevention, Pesticides, and Toxic Substances, "Bt corn has been evaluated thoroughly, ¼ and we are confident that it does not pose risks to human health or to the environment. Consumers should be assured that these corn varieties show no signs of any adverse effects to human health."

By its action EPA also extended the reach of genetically modified corn by okaying a new variety called Herculex, developed and marketed by Pioneer HiBred of Des Moines, Iowa, in collaboration with Indianapolis-based Dow AgroSciences. The agency approved the new seed, which contains a gene called ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies